BioCentury
ARTICLE | Clinical News

Genocea gains on 12-month HSV data

April 1, 2016 1:23 AM UTC

Genocea Biosciences Inc. (NASDAQ:GNCA) gained $3.77 (95%) to $7.74 on Thursday after reporting 12-month data from a Phase II trial of herpes simplex virus-2 (HSV-2) candidate GEN-003. The company believes a three-injection course of GEN-003 offers similar benefits and improved convenience compared to a year of daily oral antivirals.

Genocea said a 60 ug per protein dose with 50 or 75 ug of its Matrix-M2 adjuvant reduced viral shedding by 64% and 52%, respectively, from baseline to 12 months after treatment (p<0.0001 for both). The two doses also significantly reduced genital lesions by 65% and 47%, respectively. ...